Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally administered, direct-acting, reversible P2Y12 receptor antagonist.
## Primary Indications
* Inhibition of platelet aggregation in patients with a history of myocardial infarction (MI) or with acute coronary syndrome (ACS).
## Adult Dosing
* **ACS:** Loading dose: 180 mg orally once. Maintenance dose: 90 mg orally twice daily.
* **History of MI (≥1 year post-MI):** 60 mg orally twice daily.
## Pediatric Dosing
* Dosing in pediatric patients is not established.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is recommended for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is recommended for mild to moderate renal impairment. Use with caution in severe renal impairment.
## Contraindications
* Active pathological bleeding (e.g., intracranial hemorrhage, gastrointestinal bleed).
* History of transient ischemic attack (TIA) or stroke.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Most Common:** Dyspnea, bleeding (including major and minor), bradycardia, ventricular pauses.
* **Serious:** Life-threatening bleeding, anaphylaxis.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) may increase ticagrelor exposure; monitor for adverse effects. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease ticagrelor exposure.
* **Other Antiplatelets/Anticoagulants:** Increased risk of bleeding. Use with caution and monitor closely.
* **Proton Pump Inhibitors (PPIs):** Some studies suggest PPIs may reduce ticagrelor efficacy, particularly omeprazole and esomeprazole. The clinical significance is uncertain and debated.
* **Aspirin:** While often used concurrently, prolonged use of high-dose aspirin (>100 mg) with ticagrelor may be associated with increased bleeding risk and reduced ticagrelor efficacy.
## Monitoring
* **Bleeding:** Assess for signs and symptoms of bleeding (e.g., hematuria, melena, epistaxis, bruising).
* **Bradycardia:** Monitor heart rate.
* **Renal and Hepatic Function:** Baseline and periodic monitoring may be warranted, especially in patients with pre-existing impairment.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, meaning platelet function can recover more quickly upon discontinuation compared to clopidogrel.
* Dyspnea is a common side effect, often transient and not necessarily indicative of cardiac issues.
* The 90 mg twice daily dose is typically used for ACS, while the 60 mg twice daily dose is for long-term maintenance in patients with a history of MI.
* Discontinuation of ticagrelor, particularly within the first year of ACS, increases the risk of thrombotic events.
***
**Disclaimer:** This information is intended for educational purposes and is not a substitute for professional medical advice. Always consult the current prescribing information and relevant guidelines for complete and up-to-date drug information.
